Drugs

, Volume 72, Issue 8, pp 1029–1038 | Cite as

Epidemiology and Management of Kawasaki Disease

Therapy In Practice

Abstract

Kawasaki disease (KD) is an acute systemic vasculitis affecting young children and is rising in incidence worldwide. It is most common in children <5 years of age, males and those of Asian ethnicity. It is an important cause of acquired heart disease in children. Standard treatment with high-dose aspirin (acetylsalicylic acid; ASA) and intravenous immune globulin (IVIG) has been shown to decrease the rate of coronary artery aneurysm development. Anti-coagulation has an important place in the management of KD, although guidance based on evidence is lacking. Treatment of refractory KD is an area under intense study and may include IVIG, corticosteroids and/or tumour necrosis factor (TNF)-α inhibitors among immunosuppressive agents. Acute complications of KD include myocarditis/KD shock syndrome and macrophage activation syndrome, which necessitate appropriate awareness in order to initiate proper management.

References

  1. 1.
    Newburger JW, Takahashi M, Gerber MA, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Circulation 2004 Oct 26; 110 (17): 2747–71CrossRefPubMedGoogle Scholar
  2. 2.
    Ozen S, Ruperto N, Dillon MJ, et al. EULAR/PReS endorsed consensus criteria for the classification of childhood vasculitides. Ann Rheum Dis 2006 Jul; 65 (7): 936–41CrossRefPubMedGoogle Scholar
  3. 3.
    Kawasaki T. Acute febrile mucocutaneous syndrome with lymphoid involvement with specific desquamation of the fingers and toes in children [in Japanese]. Arerugi 1967 Mar; 16 (3): 178–222PubMedGoogle Scholar
  4. 4.
    Lin YT, Manlhiot C, Ching JC, et al. Repeated systematic surveillance of Kawasaki disease in Ontario from 1995 to 2006. Pediatr Int 2010 Oct; 52 (5): 699–706CrossRefPubMedGoogle Scholar
  5. 5.
    Holman RC, Belay ED, Christensen KY, et al. Hospitalizations for Kawasaki syndrome among children in the United States, 1997–2007. Pediatr Infect Dis J 2010 Jun; 29 (6): 483–8PubMedGoogle Scholar
  6. 6.
    Holman RC, Christensen KY, Belay ED, et al. Racial/ethnic differences in the incidence of Kawasaki syndrome among children in Hawaii. Hawaii Med J 2010 Aug; 69 (8): 194–7PubMedGoogle Scholar
  7. 7.
    Breunis WB. Inflammation @ the heart of Kawasaki disease: immunogenetic studies on etiology, pathophysiology and treatment effect [dissertation]. Amsterdam: University of Amsterdam, 2010Google Scholar
  8. 8.
    Fischer TK, Holman RC, Yorita KL, et al. Kawasaki syndrome in Denmark. Pediatr Infect Dis J 2007 May; 26 (5): 411–5CrossRefPubMedGoogle Scholar
  9. 9.
    Harnden A, Mayon-White R, Perera R, et al. Kawasaki disease in England: ethnicity, deprivation, and respiratory pathogens. Pediatr Infect Dis J 2009 Jan; 28 (1): 21–4CrossRefPubMedGoogle Scholar
  10. 10.
    Nakamura Y, Yashiro M, Uehara R, et al. Epidemiologic features of Kawasaki disease in Japan: results of the 2007–2008 nationwide survey. J Epidemiol 2010; 20 (4): 302–7CrossRefPubMedGoogle Scholar
  11. 11.
    Park YW, Han JW, Hong YM, et al. Epidemiological features of Kawasaki disease in Korea, 2006–2008. Pediatr Int 2011 Feb;53 (1): 36-9Google Scholar
  12. 12.
    Huang WC, Huang LM, Chang IS, et al. Epidemiologic features of Kawasaki disease in Taiwan, 2003–2006. Pediatrics 2009 Mar; 123 (3): e401-5Google Scholar
  13. 13.
    Ng YM, Sung RY, So LY, et al. Kawasaki disease in Hong Kong, 1994 to 2000. Hong Kong Med J 2005 Oct; 11 (5): 331–5PubMedGoogle Scholar
  14. 14.
    Du ZD, Zhao D, Du J, et al. Epidemiologic study on Kawasaki disease in Beijing from 2000 through 2004. Pediatr Infect Dis J 2007 May; 26 (5): 449–51CrossRefPubMedGoogle Scholar
  15. 15.
    Heaton P, Wilson N, Nicholson R, et al. Kawasaki disease in New Zealand. J Paediatr Child Health 2006 Apr; 42 (4): 184–90CrossRefPubMedGoogle Scholar
  16. 16.
    Royle JA, Williams K, Elliott E, et al. Kawasaki disease in Australia, 1993–95. Arch Dis Child 1998 Jan; 78 (1): 33–9CrossRefPubMedGoogle Scholar
  17. 17.
    Newburger JW, Takahashi M, Gerber MA, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Pediatrics 2004 Dec; 114 (6): 1708–33CrossRefPubMedGoogle Scholar
  18. 18.
    Sudo D, Monobe Y, Yashiro M, et al. Case-control study of giant coronary aneurysms due to Kawasaki disease: the 19th nationwide survey. Pediatr Int 2010 Oct; 52 (5): 790–4CrossRefPubMedGoogle Scholar
  19. 19.
    Kato H, Koike S, Yokoyama T. Kawasaki disease: effect of treatment on coronary artery involvement. Pediatrics 1979 Feb; 63 (2): 175–9PubMedGoogle Scholar
  20. 20.
    Baumer JH, Love SJ, Gupta A, et al. Salicylate for the treatment of Kawasaki disease in children. Cochrane Database Syst Rev 2006; (4): CD004175Google Scholar
  21. 21.
    Yin MJ, Yamamoto Y, Gaynor RB. The anti-inflammatory agents aspirin and salicylate inhibit the activity of I(kappa)B kinase-beta. Nature 1998 Nov 5; 396 (6706): 77–80CrossRefPubMedGoogle Scholar
  22. 22.
    Ichida F, Fatica NS, Engle MA, et al. Coronary artery involvement in Kawasaki syndrome in Manhattan, New York: risk factors and role of aspirin. Pediatrics 1987 Dec; 80 (6): 828–35PubMedGoogle Scholar
  23. 23.
    Furusho K, Sato K, Soeda T, et al. High-dose intravenous gammaglobulin for Kawasaki disease. Lancet 1983 Dec 10; 2 (8363): 1359Google Scholar
  24. 24.
    Furusho K, Kamiya T, Nakano H, et al. High-dose intravenous gammaglobulin for Kawasaki disease. Lancet 1984 Nov 10; 2 (8411): 1055–8CrossRefPubMedGoogle Scholar
  25. 25.
    Newburger JW, Takahashi M, Burns JC, et al. The treatment of Kawasaki syndrome with intravenous gamma globulin. N Engl J Med 1986 Aug 7; 315 (6): 341–7CrossRefPubMedGoogle Scholar
  26. 26.
    Newburger JW, Takahashi M, Beiser AS, et al. A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome. N Engl J Med 1991 Jun 6; 324 (23): 1633–9CrossRefPubMedGoogle Scholar
  27. 27.
    Oates-Whitehead RM, Baumer JH, Haines L, et al. Intravenous immunoglobulin for the treatment of Kawasaki disease in children. Cochrane Database Syst Rev 2003; (4): CD004000Google Scholar
  28. 28.
    Leung DY. The immunologic effects of IVIG in Kawasaki disease. Int Rev Immunol 1989; 5 (2): 197–202CrossRefPubMedGoogle Scholar
  29. 29.
    Lau AC, Duong TT, Ito S, et al. Intravenous immunoglobulin and salicylate differentially modulate pathogenic processes leading to vascular damage in a model of Kawasaki disease. Arthritis Rheum 2009 Jul; 60 (7): 2131–41CrossRefPubMedGoogle Scholar
  30. 30.
    Williams RV, Wilke VM, Tani LY, et al. Does Abciximab enhance regression of coronary aneurysms resulting from Kawasaki disease?. Pediatrics 2002 Jan; 109 (1): E4Google Scholar
  31. 31.
    McCandless RT, Minich LL, Tani LY, et al. Does abciximab promote coronary artery remodeling in patients with Kawasaki disease?. Am J Cardiol 2010 Jun 1; 105 (11): 1625–8CrossRefPubMedGoogle Scholar
  32. 32.
    Ashouri N, Takahashi M, Dorey F, et al. Risk factors for nonresponse to therapy in Kawasaki disease. J Pediatr 2008 Sep; 153 (3): 365–8CrossRefPubMedGoogle Scholar
  33. 33.
    Sundel RP, Baker AL, Fulton DR, et al. Corticosteroids in the initial treatment of Kawasaki disease: report of a randomized trial. J Pediatr 2003 Jun; 142 (6): 611–6CrossRefPubMedGoogle Scholar
  34. 34.
    Newburger JW, Sleeper LA, McCrindle BW, et al. Randomized trial of pulsed corticosteroid therapy for primary treatment of Kawasaki disease. N Engl J Med 2007 Feb 15; 356 (7): 663–75CrossRefPubMedGoogle Scholar
  35. 35.
    Hashino K, Ishii M, Iemura M, et al. Re-treatment for immune globulin-resistant Kawasaki disease: a comparative study of additional immune globulin and steroid pulse therapy. Pediatr Int 2001 Jun; 43 (3): 211–7CrossRefPubMedGoogle Scholar
  36. 36.
    Ogata S, Bando Y, Kimura S, et al. The strategy of immune globulin resistant Kawasaki disease: a comparative study of additional immune globulin and steroid pulse therapy. J Cardiol 2009 Feb; 53 (1): 15–9CrossRefPubMedGoogle Scholar
  37. 37.
    Furukawa T, Kishiro M, Akimoto K, et al. Effects of steroid pulse therapy on immunoglobulin-resistant Kawasaki disease. Arch Dis Child 2008 Feb; 93 (2): 142–6CrossRefPubMedGoogle Scholar
  38. 38.
    Hui-Yuen JS, Duong TT, Yeung RS. TNF-alpha is necessary for induction of coronary artery inflammation and aneurysm formation in an animal model of Kawasaki disease. J Immunol 2006 May 15; 176 (10): 6294–301PubMedGoogle Scholar
  39. 39.
    Burns JC, Mason WH, Hauger SB, et al. Infliximab treatment for refractory Kawasaki syndrome. J Pediatr 2005 May; 146 (5): 662–7CrossRefPubMedGoogle Scholar
  40. 40.
    Burns JC, Best BM, Mejias A, et al. Infliximab treatment of intravenous immunoglobulin-resistant Kawasaki disease. J Pediatr 2008 Dec; 153 (6): 833–8CrossRefPubMedGoogle Scholar
  41. 41.
    Son MB, Gauvreau K, Burns JC, et al. Infliximab for intravenous immunoglobulin resistance in Kawasaki disease: a retrospective study. J Pediatr 2011 Apr; 158 (4): 644–9CrossRefPubMedGoogle Scholar
  42. 42.
    Hirono K, Kemmotsu Y, Wittkowski H, et al. Infliximab reduces the cytokine-mediated inflammation but does not suppress cellular infiltration of the vessel wall in refractory Kawasaki disease. Pediatr Res 2009 Jun; 65 (6): 696–701CrossRefPubMedGoogle Scholar
  43. 43.
    Choueiter NF, Olson AK, Shen DD, et al. Prospective open-label trial of etanercept as adjunctive therapy for kawasaki disease. J Pediatr 2010 Dec; 157 (6): 960–6.e1CrossRefPubMedGoogle Scholar
  44. 44.
    Portman MA, Olson A, Soriano B, et al. Etanercept as adjunctive treatment for acute Kawasaki disease: study design and rationale. Am Heart J 2011 Mar; 161 (3): 494–9CrossRefPubMedGoogle Scholar
  45. 45.
    Benseler SM, McCrindle BW, Silverman ED, et al. Infections and Kawasaki disease: implications for coronary artery outcome. Pediatrics 2005 Dec; 116 (6): e760–6Google Scholar
  46. 46.
    Suzuki H, Terai M, Hamada H, et al. Cyclosporin A treatment for Kawasaki disease refractory to initial and additional intravenous immunoglobulin. Pediatr Infect Dis J 2011 Oct; 30 (10): 871–6CrossRefPubMedGoogle Scholar
  47. 47.
    Wallace CA, French JW, Kahn SJ, et al. Initial intravenous gammaglobulin treatment failure in Kawasaki disease. Pediatrics 2000 Jun; 105 (6): E78Google Scholar
  48. 48.
    Uehara R, Yashiro M, Oki I, et al. Re-treatment regimens for acute stage of Kawasaki disease patients who failed to respond to initial intravenous immunoglobulin therapy: analysis from the 17th nationwide survey. Pediatr Int 2007 Aug; 49 (4): 427–30CrossRefPubMedGoogle Scholar
  49. 49.
    Kanegaye JT, Wilder MS, Molkara D, et al. Recognition of a Kawasaki disease shock syndrome. Pediatrics 2009 May; 123 (5): e783–9Google Scholar
  50. 50.
    Newburger JW, Sanders SP, Burns JC, et al. Left ventricular contractility and function in Kawasaki syndrome: effect of intravenous gamma-globulin. Circulation 1989 Jun; 79 (6): 1237–46CrossRefPubMedGoogle Scholar
  51. 51.
    Latino GA, Manlhiot C, Yeung RS, et al. Macrophage activation syndrome in the acute phase of Kawasaki disease. J Pediatr Hematol Oncol 2010 Oct; 32 (7): 527–31CrossRefPubMedGoogle Scholar
  52. 52.
    Muise A, Tallett SE, Silverman ED. Are children with Kawasaki disease and prolonged fever at risk for macrophage activation syndrome?. Pediatrics 2003 Dec; 112 (6 Pt 1): e495Google Scholar
  53. 53.
    Titze U, Janka G, Schneider EM, et al. Hemophagocytic lymphohistiocytosis and Kawasaki disease: combined manifestation and differential diagnosis. Pediatr Blood Cancer 2009 Sep; 53 (3): 493–5CrossRefPubMedGoogle Scholar
  54. 54.
    Chen Y, Shang S, Zhang C, et al. Hemophagocytic lymphohistiocytosis at initiation of kawasaki disease and their differential diagnosis. Pediatr Hematol Oncol 2010 Apr; 27 (3): 244–9CrossRefPubMedGoogle Scholar
  55. 55.
    Kim HK, Kim HG, Cho SJ, et al. Clinical characteristics of hemophagocytic lymphohistiocytosis related to Kawasaki disease. Pediatr Hematol Oncol 2011 Apr; 28 (3): 230–6PubMedGoogle Scholar
  56. 56.
    Henter JI, Horne A, Arico M, et al. HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lympho-histiocytosis. Pediatr Blood Cancer 2007 Feb; 48 (2): 124–31CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG 2012

Authors and Affiliations

  1. 1.Department of PediatricsUniversity of TorontoTorontoCanada
  2. 2.Division of RheumatologyThe Hospital for Sick ChildrenTorontoCanada
  3. 3.Department of ImmunologyUniversity of TorontoCanada
  4. 4.Institute of Medical ScienceUniversity of TorontoTorontoCanada

Personalised recommendations